Literature DB >> 8697676

Therapy dose calculation in Graves' disease using early I-123 uptake measurements.

U S Vemulakonda1, F B Atkins, H A Ziessman.   

Abstract

A retrospective study was performed to assess the feasibility of using the 4-hour I-123 early uptake value in the calculation of the treatment dose of radioactive iodine in Graves' disease patients. The Graves' disease patients were randomly divided into two groups. Data from the first group of 35 patients were used to obtain a regression relationship between the early 4-hour uptake (EUp) and 24-hour late uptake values (LUp). This equation, LUp = -38.618 + 65.216 Log (EUp) was used to estimate the predicted late uptake (PUp) from (EUp) in the second group of 34 patients. LUp was used to calculate the I-131 therapy dose for treatment in these patients. In 28 clinically euthyroid patients, the 4-hour uptake I-123 radioactive iodine uptake (RAIU) ranged from 7% to 20% (mean, 12 +/- 3.5%). In 60 Graves' disease patients, the 4-hour RAIU ranged from 15% to 100% (mean, 57 +/- 24.8%). Of these, there were five patients with a normal 4-hour uptake, but elevated 24-hour uptake. LUp correlated well with PUp (r = 0.81162), as did the dose calculation based on predicted and observed 24-hour uptake values (r = 0.82204). Thus, same day measurement of uptake and treatment of Graves' disease is feasible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8697676     DOI: 10.1097/00003072-199602000-00004

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

1.  Prediction of post-treatment hypothyroidism using changes in thyroid volume after radioactive iodine therapy in adolescent patients with Graves' disease.

Authors:  Nobuhiro Nakatake; Shuji Fukata; Junichi Tajiri
Journal:  Int J Pediatr Endocrinol       Date:  2011-11-07

2.  Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (99mTc) scintigraphy.

Authors:  Piotr Szumowski; Małgorzata Mojsak; Saeid Abdelrazek; Monika Sykała; Anna Amelian-Fiłonowicz; Dorota Jurgilewicz; Janusz Myśliwiec
Journal:  Endocrine       Date:  2016-08-24       Impact factor: 3.633

3.  Dosimetry-based treatment for Graves' disease.

Authors:  Steve L Hyer; Brenda Pratt; Matthew Gray; Sarah Chittenden; Yong Du; Clive L Harmer; Glenn D Flux
Journal:  Nucl Med Commun       Date:  2018-06       Impact factor: 1.690

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.